Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead/J&J NDA Could Mean Another Fixed-Dose Regimen For HIV

This article was originally published in The Pink Sheet Daily

Executive Summary

The pill combines J&J’s blockbuster protease inhibitor Prezista (duranavir) with Gilead’s boosting agent cobicistat. Currently, Prezista is required to be administered with the boosting agent ritonavir.

You may also be interested in...



The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild

With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.

Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact

The two companies hope to repeat their Atripla success story by teaming up to develop a new combination drug for HIV containing Gilead's cobicistat and Bristol's atazanavir.

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS077066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel